Skip to main content

Stories by Thomas Maeder

The Orphan Drug Backlash

The Orphan Drug Act of 1983 was supposed to provide incentives for private industry to develop needed, but unprofitable, drugs to treat rare diseases. It has done so, but not without eliciting controversy

April 14, 2003 — Thomas Maeder

Sweet Medicines

Sugars play critical roles in many cellular functions and in disease. Study of those activities lags behind research into genes and proteins but is beginning to heat up. The discoveries promise to yield a new generation of drug therapies

June 17, 2002 — Thomas Maeder

Back to School

Get 50% off digital subscriptions of Scientific American and Scientific American MIND!